A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16â¯week randomized placebo-controlled trial for participants concurrently treated with risperidone.
Schizophr Res
; 204: 295-303, 2019 02.
Article
en En
| MEDLINE
| ID: mdl-30241990
ABSTRACT
Omega-3 treatment studies for multi-episode schizophrenia or clinical high risk for conversion to psychosis states have had variable, and often negative, results. To examine adjunctive omega-3 treatment for recent onset psychosis, participants aged 15-40â¯years with recent onset schizophrenia-spectrum (nâ¯=â¯46) or bipolar (nâ¯=â¯4) disorders and current psychotic symptoms were treated for 16â¯weeks with risperidone and randomly-assigned omega-3 (EPA 740â¯mg and DHA 400â¯mg daily) or matching placebo. The primary outcome measure was the Brief Psychiatric Rating Scale (BPRS) total score. Mean lifetime antipsychotic exposure was 18.1â¯days. Length of time in treatment, risperidone dose and number of omega-3/placebo capsules taken did not differ between conditions. Longitudinal analysis of the total BPRS score revealed a trend level (pâ¯=â¯0.0826) treatment effect favoring omega-3 treatment. Lorazepam was an allowed concomitant medication. Among the subgroup (Nâ¯=â¯23) who did not receive lorazepam, the treatment effect on BPRS total scores favoring omega-3 was significant (pâ¯=â¯0.0406) and factor scores analyses revealed a substantial decrease in depression-anxiety with omega-3 but no change with placebo (treatment-by-time interaction, pâ¯=â¯0.0184). Motor side effects did not differ between conditions. Analysis of Systematic Assessment for Treatment Emergent Events assessments revealed fewer adverse events overall with omega-3 compared with placebo with the largest differences between conditions (all favoring omega-3) on confusion, anxiety, depression, irritability, and tiredness/fatigue. These results suggest that omega-3 adjuvant treatment is a potential option for depression and anxiety symptoms of people with recent onset psychosis. Further research is needed to confirm this potential. Clinical trial registration NCT01786239.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Ansiedad
/
Trastornos Psicóticos
/
Esquizofrenia
/
Antipsicóticos
/
Trastorno Bipolar
/
Ácidos Grasos Omega-3
/
Risperidona
/
Depresión
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
/
Etiology_studies
Idioma:
En
Revista:
Schizophr Res
Año:
2019
Tipo del documento:
Article